Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
ARQTArcutis Biotherapeutics(ARQT) Newsfilter·2024-07-29 19:30

Once-daily, effective, safe, and well-tolerated ZORYVE cream now commercially availableProvides rapid clearance of atopic dermatitis signs and symptoms and significant reduction in itch, and can be used anywhere on the body for any duration to maintain clear skinAtopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children and 16.5 million adults in the United StatesManagement will host an investor event with a key opinion leader on Monday, July 29 at 8:30 am EDT/5:30 am ...